FDA Brief

Warning letters Food

FDA warning letter to

Nutrishus Brands, Inc.

LowIssued Jul 28, 2021Posted Jul 28, 2021Center for Food Safety and Applied Nutrition (CFSAN)

FDA warned Nutrishus Brands that its RxSugar sweeteners were unapproved new drugs and misbranded foods due to website disease and health claims.

What happened

In May 2021, FDA reviewed therxsugar.com and found the company took orders for RxSugar, RxSugar Organic Liquid Sugar, and RxSugar Organic Pancake Syrup. FDA said website claims tied allulose to obesity, diabetes, inflammation, and heart disease, making the products unapproved new drugs. FDA also said the products were misbranded foods because labels and website claims did not meet food naming, nutrient-content, and Nutrition Facts requirements.

What FDA found

  1. Website claims that the products' allulose may benefit obesity, diabetes, inflammation, or heart disease make them unapproved new drugs.

    section 201(g)(1)(B) and 201(p) of the Act [21 U.S.C. 321(g)(1)(B), 321(p)]; sections 301(d) and 505(a) [21 U.S.C. 331(d), 355(a)]
  2. The products are misbranded drugs because they lack adequate directions for use for diseases that require a licensed practitioner.

    section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]; 21 CFR 201.5
  3. RxSugar and RxSugar Organic Liquid Sugar labels do not show the common or usual food name, allulose.

    section 403(i)(1) [21 U.S.C. 343(i)(1)]; 21 CFR 101.3(b)(2)
  4. The website's 'Healthy' and 'Healthiest' claims are nutrient content claims, but the products do not meet FDA's requirements for 'healthy'.

    section 403(r)(1)(A) [21 U.S.C. 343(r)(1)(A)]; 21 CFR 101.65(d)(2)
  5. The '90% less Calories than Traditional Sugar' claim lacks the required nearby quantitative comparison to the reference food.

    section 403(r)(1)(A) [21 U.S.C. 343(r)(1)(A)]; 21 CFR 101.60(b)(4)
  6. The pancake syrup Nutrition Facts label uses the wrong serving size and RACC, and the simplified labels omit a required 'Not a significant source' statement.

    section 403(q) [21 U.S.C. 343(q)]; 21 CFR 101.9; 21 CFR 101.9(f)(4)

What FDA wants

FDA asks Nutrishus Brands to respond in writing within 15 working days with the specific corrections it is making, supporting documentation, and plans to prevent recurrence, or to explain why corrections cannot be completed and when they will be.

Who should pay attention

  • food brands selling sweeteners or allulose products
  • companies making disease or health claims on product websites
  • food label compliance and regulatory teams handling nutrient claims

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk